In yet another setback for Ranbaxy Laboratories Ltd, the US health regulator banned the import of products from its fourth plant (located in Punjab) citing manufacturing norm violations. This marks the halt of the shipment of all the company's drugs to the US from India. Following the announcement, Ranbaxyâ€™s share went down 19.54% to Rs 335.65 on BSE.